Published in Cancer Res on August 15, 2004
Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta (2007) 3.24
From antimicrobial to anticancer peptides. A review. Front Microbiol (2013) 1.56
Membrane-active host defense peptides--challenges and perspectives for the development of novel anticancer drugs. Chem Phys Lipids (2011) 1.45
In search of a novel target - phosphatidylserine exposed by non-apoptotic tumor cells and metastases of malignancies with poor treatment efficacy. Biochim Biophys Acta (2011) 1.36
Oncolytic activities of host defense peptides. Int J Mol Sci (2011) 1.00
Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells. BMC Urol (2008) 0.98
Coassembled cytotoxic and pegylated peptide amphiphiles form filamentous nanostructures with potent antitumor activity in models of breast cancer. ACS Nano (2012) 0.97
A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer (2011) 0.97
PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer. Mol Immunol (2008) 0.92
Small lytic peptides escape the inhibitory effect of heparan sulfate on the surface of cancer cells. BMC Cancer (2011) 0.88
Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity. J Biol Chem (2011) 0.87
Two hits are better than one: synergistic anticancer activity of α-helical peptides and doxorubicin/epirubicin. Oncotarget (2015) 0.86
Learning from host-defense peptides: cationic, amphipathic peptoids with potent anticancer activity. PLoS One (2014) 0.84
The zebrafish embryo as a tool for screening and characterizing pleurocidin host-defense peptides as anti-cancer agents. Dis Model Mech (2011) 0.83
Suppression of soft tissue sarcoma growth by a host defense-like lytic peptide. PLoS One (2011) 0.82
Acyl-substituted dermaseptin S4 derivatives with improved bactericidal properties, including on oral microflora. Antimicrob Agents Chemother (2006) 0.82
Physicochemical properties that enhance discriminative antibacterial activity of short dermaseptin derivatives. Antimicrob Agents Chemother (2006) 0.80
The anti-angiogenic peptide anginex disrupts the cell membrane. J Mol Biol (2005) 0.79
Novel antimicrobial peptides with high anticancer activity and selectivity. PLoS One (2015) 0.79
Targeting FOSB with a cationic antimicrobial peptide, TP4, for treatment of triple-negative breast cancer. Oncotarget (2016) 0.78
Online monitoring of metabolism and morphology of peptide-treated neuroblastoma cancer cells and keratinocytes. J Bioenerg Biomembr (2011) 0.78
Roles of d-Amino Acids on the Bioactivity of Host Defense Peptides. Int J Mol Sci (2016) 0.77
D-K6L 9 peptide combination with IL-12 inhibits the recurrence of tumors in mice. Arch Immunol Ther Exp (Warsz) (2014) 0.76
Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer. Mol Cancer Ther (2014) 0.76
Anti-proliferative effect on a colon adenocarcinoma cell line exerted by a membrane disrupting antimicrobial peptide KL15. Cancer Biol Ther (2015) 0.75
Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model. Mol Ther (2017) 0.75
Antimicrobial peptides with selective antitumor mechanisms: prospect for anticancer applications. Oncotarget (2017) 0.75
Intramembrane attenuation of the TLR4-TLR6 dimer impairs receptor assembly and reduces microglia mediated neurodegeneration. J Biol Chem (2017) 0.75
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res (2006) 7.09
A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol (2009) 2.43
Ultrashort antibacterial and antifungal lipopeptides. Proc Natl Acad Sci U S A (2006) 2.15
Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible modes of action. J Biol Chem (2005) 1.72
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest (2004) 1.70
Redirected tumor-specific allogeneic T cells for universal treatment of cancer. Blood (2011) 1.69
Redirection of regulatory T cells with predetermined specificity for the treatment of experimental colitis in mice. Gastroenterology (2008) 1.61
T-cell inactivation and immunosuppressive activity induced by HIV gp41 via novel interacting motif. FASEB J (2006) 1.57
Conjugation of a magainin analogue with lipophilic acids controls hydrophobicity, solution assembly, and cell selectivity. Biochemistry (2002) 1.49
Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood (2004) 1.43
Can we predict biological activity of antimicrobial peptides from their interactions with model phospholipid membranes? Peptides (2003) 1.42
Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res (2002) 1.40
New lytic peptides based on the D,L-amphipathic helix motif preferentially kill tumor cells compared to normal cells. Biochemistry (2003) 1.37
Exploring peptide membrane interaction using surface plasmon resonance: differentiation between pore formation versus membrane disruption by lytic peptides. Biochemistry (2003) 1.33
The consequence of sequence alteration of an amphipathic alpha-helical antimicrobial peptide and its diastereomers. J Biol Chem (2002) 1.30
Lipopolysaccharide (Endotoxin)-host defense antibacterial peptides interactions: role in bacterial resistance and prevention of sepsis. Biochim Biophys Acta (2006) 1.29
Bestowing antifungal and antibacterial activities by lipophilic acid conjugation to D,L-amino acid-containing antimicrobial peptides: a plausible mode of action. Biochemistry (2003) 1.25
Energetics of ErbB1 transmembrane domain dimerization in lipid bilayers. Biophys J (2009) 1.24
A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid. J Biol Chem (2004) 1.23
A molecular mechanism for lipopolysaccharide protection of Gram-negative bacteria from antimicrobial peptides. J Biol Chem (2005) 1.23
Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int J Cancer (2003) 1.19
Antimicrobial lipopolypeptides composed of palmitoyl Di- and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry (2008) 1.19
Effect of drastic sequence alteration and D-amino acid incorporation on the membrane binding behavior of lytic peptides. Biochemistry (2004) 1.18
Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. Cancer Res (2006) 1.18
Transmembrane domains interactions within the membrane milieu: principles, advances and challenges. Biochim Biophys Acta (2011) 1.16
Epigen, the last ligand of ErbB receptors, reveals intricate relationships between affinity and mitogenicity. J Biol Chem (2004) 1.14
Demonstrating the C-terminal boundary of the HIV 1 fusion conformation in a dynamic ongoing fusion process and implication for fusion inhibition. FASEB J (2007) 1.14
Two motifs within a transmembrane domain, one for homodimerization and the other for heterodimerization. J Biol Chem (2004) 1.14
Specificity in transmembrane helix-helix interactions mediated by aromatic residues. J Biol Chem (2007) 1.13
Viral fusion proteins: multiple regions contribute to membrane fusion. Biochim Biophys Acta (2003) 1.12
The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors. J Mol Biol (2004) 1.10
A novel lytic peptide composed of DL-amino acids selectively kills cancer cells in culture and in mice. J Biol Chem (2003) 1.10
Structurally altered peptides reveal an important role for N-terminal heptad repeat binding and stability in the inhibitory action of HIV-1 peptide DP178. J Biol Chem (2006) 1.09
Lipid clustering by three homologous arginine-rich antimicrobial peptides is insensitive to amino acid arrangement and induced secondary structure. Biochim Biophys Acta (2010) 1.08
Thermodynamics of melittin binding to lipid bilayers. Aggregation and pore formation. Biochemistry (2009) 1.07
Growth inhibition of prostate cancer xenografts by halofuginone. Prostate (2002) 1.07
A synergism between temporins toward Gram-negative bacteria overcomes resistance imposed by the lipopolysaccharide protective layer. J Biol Chem (2006) 1.06
Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem J (2005) 1.06
Controlled alteration of the shape and conformational stability of alpha-helical cell-lytic peptides: effect on mode of action and cell specificity. Biochem J (2005) 1.05
D-alanylation of lipoteichoic acids confers resistance to cationic peptides in group B streptococcus by increasing the cell wall density. PLoS Pathog (2012) 1.05
Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action. Cell Mol Life Sci (2011) 1.04
In vitro activity and potency of an intravenously injected antimicrobial peptide and its DL amino acid analog in mice infected with bacteria. Antimicrob Agents Chemother (2004) 1.04
Photodynamic therapy of established prostatic adenocarcinoma with TOOKAD: a biphasic apparent diffusion coefficient change as potential early MRI response marker. Neoplasia (2004) 1.03
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
Characterization of the HIV N-terminal fusion peptide-containing region in context of key gp41 fusion conformations. J Biol Chem (2006) 1.02
Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes. Cancer Res (2003) 1.01
Inhibition of fungal and bacterial plant pathogens in vitro and in planta with ultrashort cationic lipopeptides. Appl Environ Microbiol (2007) 1.01
pH-dependent antifungal lipopeptides and their plausible mode of action. Biochemistry (2005) 1.01
Functional and structural characterization of HIV-1 gp41 ectodomain regions in phospholipid membranes suggests that the fusion-active conformation is extended. J Mol Biol (2006) 1.00
Oncolytic activities of host defense peptides. Int J Mol Sci (2011) 1.00
Suppression of human solid tumor growth in mice by intratumor and systemic inoculation of histidine-rich and pH-dependent host defense-like lytic peptides. Cancer Res (2009) 1.00
Preassembly of membrane-active peptides is an important factor in their selectivity toward target cells. Biochemistry (2002) 1.00
C-terminal octylation rescues an inactive T20 mutant: implications for the mechanism of HIV/SIMIAN immunodeficiency virus-induced membrane fusion. J Biol Chem (2003) 0.99
Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor. Biochim Biophys Acta (2011) 0.99
HIV-1 gp41 transmembrane domain interacts with the fusion peptide: implication in lipid mixing and inhibition of virus-cell fusion. Biochemistry (2012) 0.99
Comparative analysis of membrane-associated fusion peptide secondary structure and lipid mixing function of HIV gp41 constructs that model the early pre-hairpin intermediate and final hairpin conformations. J Mol Biol (2010) 0.99
Lipopolysaccharide, a key molecule involved in the synergism between temporins in inhibiting bacterial growth and in endotoxin neutralization. J Biol Chem (2008) 0.99
Irradiation enhances the metastatic potential of prostatic small cell carcinoma xenografts. Prostate (2008) 0.97
Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology (2009) 0.97
Effect of the hydrophobicity to net positive charge ratio on antibacterial and anti-endotoxin activities of structurally similar antimicrobial peptides. Biochemistry (2010) 0.97
Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides. Biochemistry (2008) 0.97
Mechanistic and functional studies of the interaction of a proline-rich antimicrobial peptide with mammalian cells. J Biol Chem (2005) 0.96
On the interaction between gp41 and membranes: the immunodominant loop stabilizes gp41 helical hairpin conformation. J Mol Biol (2003) 0.96
Utilizing ESEEM spectroscopy to locate the position of specific regions of membrane-active peptides within model membranes. Biophys J (2005) 0.96
HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation. J Clin Invest (2005) 0.96
Membrane-anchored HIV-1 N-heptad repeat peptides are highly potent cell fusion inhibitors via an altered mode of action. PLoS Pathog (2009) 0.95
W-Band pulse EPR distance measurements in peptides using Gd(3+)-dipicolinic acid derivatives as spin labels. Phys Chem Chem Phys (2011) 0.95
Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lys. Antimicrob Agents Chemother (2008) 0.95
The HIV-1 gp41 N-terminal heptad repeat plays an essential role in membrane fusion. Biochemistry (2002) 0.95
Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology (2012) 0.94
Impairment of innate immune killing mechanisms by bacteriostatic antibiotics. FASEB J (2007) 0.94
Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. J Biol Chem (2002) 0.94
Hairpin folding of HIV gp41 abrogates lipid mixing function at physiologic pH and inhibits lipid mixing by exposed gp41 constructs. Biochemistry (2009) 0.93
Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides. Eur Biophys J (2011) 0.93
The HIV fusion peptide adopts intermolecular parallel beta-sheet structure in membranes when stabilized by the adjacent N-terminal heptad repeat: a 13C FTIR study. J Mol Biol (2005) 0.93
The C- and the N-terminal regions of glycoprotein 41 ectodomain fuse membranes enriched and not enriched with cholesterol, respectively. J Biol Chem (2004) 0.92
Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer. Expert Opin Biol Ther (2014) 0.92
Membrane integration of a mitochondrial signal-anchored protein does not require additional proteinaceous factors. Biochem J (2012) 0.92
HIV-1 gp41 and TCRalpha trans-membrane domains share a motif exploited by the HIV virus to modulate T-cell proliferation. PLoS Pathog (2010) 0.92
Conformational stability and membrane interaction of the full-length ectodomain of HIV-1 gp41: implication for mode of action. Biochemistry (2009) 0.91
Temporins and their synergism against Gram-negative bacteria and in lipopolysaccharide detoxification. Biochim Biophys Acta (2009) 0.90
Hetero-assembly between all-L- and all-D-amino acid transmembrane domains: forces involved and implication for inactivation of membrane proteins. J Mol Biol (2004) 0.90
Artificial beta-defensin based on a minimal defensin template. Biochem J (2009) 0.90
Effect of natural L- to D-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H. Biochemistry (2006) 0.90
The identification of a minimal dimerization motif QXXS that enables homo- and hetero-association of transmembrane helices in vivo. J Biol Chem (2005) 0.88
Quantitative detection of protein arrays. Anal Chem (2003) 0.88
Investigation of model membrane disruption mechanism by melittin using pulse electron paramagnetic resonance spectroscopy and cryogenic transmission electron microscopy. J Phys Chem B (2011) 0.87
Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. Prostate (2009) 0.87
New insights into the mechanism of virus-induced membrane fusion. Trends Biochem Sci (2002) 0.87
Effect of PhoP-PhoQ activation by broad repertoire of antimicrobial peptides on bacterial resistance. J Biol Chem (2011) 0.87
Viral envelope protein folding and membrane hemifusion are enhanced by the conserved loop region of HIV-1 gp41. FASEB J (2011) 0.86
Structures and mode of membrane interaction of a short alpha helical lytic peptide and its diastereomer determined by NMR, FTIR, and fluorescence spectroscopy. Eur J Biochem (2002) 0.86
Esterolytic antibodies as mechanistic and structural models of hydrolases-a quantitative analysis. J Mol Biol (2002) 0.86
Virus-cell and cell-cell fusion mediated by the HIV-1 envelope glycoprotein is inhibited by short gp41 N-terminal membrane-anchored peptides lacking the critical pocket domain. FASEB J (2010) 0.86
D-enantiomer peptide of the TCRalpha transmembrane domain inhibits T-cell activation in vitro and in vivo. FASEB J (2005) 0.86
The composition rather than position of polar residues (QxxS) drives aspartate receptor transmembrane domain dimerization in vivo. Biochemistry (2004) 0.85
A structurally altered D,L-amino acid TCRalpha transmembrane peptide interacts with the TCRalpha and inhibits T-cell activation in vitro and in an animal model. Biochemistry (2007) 0.85
The GBS PI-2a pilus is required for virulence in mice neonates. PLoS One (2011) 0.85
Characterization of the interacting domain of the HIV-1 fusion peptide with the transmembrane domain of the T-cell receptor. Biochemistry (2008) 0.85